Soliris (eculizumab) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 85 Diseases   29 Trials   29 Trials   4783 News 


«12...3132333435363738394041...5960»
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    [VIRTUAL] Where Did the TMA Come From, Where Did It Go: A Kidney Transplant Cotton-Eye Joe () -  Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_776;    
    Cyclosporine was substituted for tacrolimus due to suspicion of tacrolimus-induced TMA...The patient was treated with three cycles of eculizumab and sCr trended down to 1.8 mg/dL...The definitive etiology of the donor-derived TMA is uncertain based on lacking clinical history of the donor. Our patient developed clinical TMA after receiving a donor kidney with pathological evidence of TMA with eventual resolution of clinical and pathological evidence over a period of time.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    [VIRTUAL] Post-operative Thrombotic Microangiopathy causing Renal Failure () -  Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_690;    
    CONCLUSION We present this case of renal failure post-uterine myomectomy from aHUS associated TMA, effectively treated with eculizumab. Further investigation into NSAID-associated TMA and the pathophysiology of post-operative TMA is prudent for early treatment and preservation of renal function.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Soliris (eculizumab) / Alexion Pharma
    [VIRTUAL] Hyperacute Rejection of Kidney Transplant: Is Salvage of Graft Possible? () -  Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_607;    
    The patient was maintained on prednisone, mycophenolate mofetil and tacrolimus...Despite the extensive workup, etiology was never found. CONCLUSION nil
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    [VIRTUAL] Eculizumab Therapy for Gemcitabine-induced Atypical Hemolytic Uremic Syndrome () -  Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_562;    
    CONCLUSION Medication-induced aHUS is traditionally treated with cessation of the drug with or without plasmapheresis. However, given the growing understanding of the underlying mechanism of aHUS involving the alternative complement system, eculizumab, a monoclonal antibody that inhibits the activation of alternative complement cascade, is potentially helpful in patients with gemcitabine-induced aHUS progressing after holding gemcitabine.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    [VIRTUAL] A rare case of atypical hemolytic uremic syndrome and primary membranous nephropathy with novel findings () -  Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_447;    
    The coexistence of these two conditions in the same individual is likely unrelated as no complement factor autoantibodies have been found although further testing will be necessary. Long term therapy with complement blockade will be necessary, and IS therapy with rituximab will be instituted CONCLUSION Coexistence of kidney diseases of multiple etiologies as in this case is very uncommon, this case provides a good example of multiple and diverse etiologic factors affecting the kidney.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    [VIRTUAL] A case of concurrent HELLP and pregnancy associated atypical HUS (aHUS) during postpartum period () -  Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_432;    
    Although liver function normalized, hemolysis & AKI persisted resulting in patient being put on regular dialysis with a plan for genetic testing & initiation of Eculizumab therapy...CONCLUSION MAHA in peripartum period continues to be a diagnostic & therapeutic challenge. It is essential to recognize the potential for coexistence of various overlapping syndromes & develop effective diagnostic & therapeutic strategies to help reverse the effect of various syndromes.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Journal:  Two patients, two viruses and multiple sites of injury in the kidney. (Pubmed Central) -  Feb 26, 2021   
    We present two patients presented with acute kidney injury and thrombocytopenia caused by different viruses (Hantavirus and HIV) that affect multiple areas in kidney that revealed with kidney biopsy. Supportive treatment in the patient with Hantavirus nephropathy and HIV treatment along with eculizumab and supportive treatment in the patient with HIVAN were successfully implemented.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Current and Emerging Biologics for the Treatment of Neuromyelitis Optica Spectrum Disorders. (Pubmed Central) -  Feb 23, 2021   
    The interleukin-6 receptor inhibitor satralizumab and anti-CD19 antibody inebilizumab have published positive phase III trial results and await approval in the near future...Although we will have even more evidence-based therapy options in the future, empirically used medications will keep their importance for now. The potential effect of new medications in AQP4 antibody seronegative NMOSD and patients with an NMOSD phenotype and antibodies to myelin oligodendrocyte glycoprotein (MOG) remains to be determined.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Eculizumab for the treatment of myasthenia gravis. (Pubmed Central) -  Feb 23, 2021   
    At present we are missing a controlled study on its use as a first-line treatment. We think that immunosuppression in MG will change significantly in the next years by adopting more focused 'Precision Medicine' approaches, and Eculizumab seems to satisfy such a promise.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Ultomiris IV (ravulizumab IV) / Alexion Pharma
    Clinical guideline, Journal:  Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. (Pubmed Central) -  Feb 23, 2021   
    ACIP recommends MenACWY booster doses for previously vaccinated persons who become or remain at increased risk.In addition, ACIP recommends routine use of MenB vaccine series among persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease, including persons who have persistent complement component deficiencies; persons receiving a complement inhibitor; persons who have anatomic or functional asplenia; microbiologists who are routinely exposed to isolates of N. meningitidis; and persons identified to be at increased risk because of a meningococcal disease outbreak caused by serogroup B. ACIP recommends MenB booster doses for previously vaccinated persons who become or remain at increased risk. In addition, ACIP recommends a MenB series for adolescents and young adults aged 16-23 years on the basis of shared clinical decision-making to provide short-term protection against disease caused by most strains of serogroup B N. meningitidis.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus. (Pubmed Central) -  Feb 20, 2021   
    We suggest a sum score to define treatment refractory state in generalised myasthenia gravis. Beyond clarifying the indication of eculizumab, this easy-to-handle score facilitates clinical decision making and offers new inclusion criteria for clinical studies that explore new therapeutic perspectives in myasthenia gravis treatment.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Trial completion date, Trial primary completion date:  An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients (clinicaltrials.gov) -  Feb 17, 2021   
    P3,  N=119, Active, not recruiting, 
    Beyond clarifying the indication of eculizumab, this easy-to-handle score facilitates clinical decision making and offers new inclusion criteria for clinical studies that explore new therapeutic perspectives in myasthenia gravis treatment. Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Clinical, Clinical Trial,Phase I, Journal:  C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. (Pubmed Central) -  Feb 17, 2021   
    All four subjects who completed the study transitioned to pegcetacoplan monotherapy following eculizumab discontinuation and avoided transfusions. In this small study, pegcetacoplan therapy was generally well-tolerated, and resulted in an improved hematological response by achieving broad hemolysis control, enabling eculizumab discontinuation.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / Alexion Pharma
    Review, Journal:  Current treatment in COVID-19 disease: a rapid review. (Pubmed Central) -  Feb 12, 2021   
    This review aims to assess the efficacy and safety of these available therapies in light of current evidence. We compare these treatment options based on their impact on symptom management, inpatient length of stay, and overall morbidity and mortality.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Middle level IM-MS and CIU experiments for improved therapeutic immunoglobulin subclass fingerprinting. (Pubmed Central) -  Feb 11, 2021   
    The unfolding signatures of both domains allowed to corroborate, within a single run, the hybrid nature of eculizumab as well as specific subclass domain assignments to the F(ab')2 and Fc regions. Alto-gether, our results confirm the suitability of middle-level CIU of F(ab')2 domains for subclass categorization of canonical and more complex new generation engineered antibodies and related products.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Review, Journal:  Toddler With New Onset Diabetes and Atypical Hemolytic Uremic Syndrome in the Setting of COVID-19. (Pubmed Central) -  Feb 10, 2021   
    Alto-gether, our results confirm the suitability of middle-level CIU of F(ab')2 domains for subclass categorization of canonical and more complex new generation engineered antibodies and related products. This patient demonstrated remarkable insulin resistance in the period before aHUS diagnosis, which resolved with the first dose of eculizumab therapy...No abstract available
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Ultomiris IV (ravulizumab IV) / Alexion Pharma
    [VIRTUAL] CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING C5 INHIBITORS (ePoster Area) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_3086;    
    Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening hematological disease associated with a significant burden of illness (BOI) due to complement-mediated hemolysis and a subsequent need for blood transfusions that often persists despite standard treatment with the C5 inhibitors eculizumab (ECU) or ravulizumab (RAV).  Findings from this BOI survey demonstrate that there is a significant unmet medical need among PNH patients, with a majority of PNH patients remaining anemic and reporting fatigue, and a notable number of PNH patients requiring blood transfusions, despite treatment with C5 inhibitors for at least 3 months.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Ultomiris IV (ravulizumab IV) / Alexion Pharma
    [VIRTUAL] CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING C5 INHIBITORS (ePoster Area) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_3085;    
    Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening hematological disease associated with a significant burden of illness (BOI) due to complement-mediated hemolysis and a subsequent need for blood transfusions that often persists despite standard treatment with the C5 inhibitors eculizumab (ECU) or ravulizumab (RAV).  Findings from this BOI survey demonstrate that there is a significant unmet medical need among PNH patients, with a majority of PNH patients remaining anemic and reporting fatigue, and a notable number of PNH patients requiring blood transfusions, despite treatment with C5 inhibitors for at least 3 months.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Ultomiris IV (ravulizumab IV) / Alexion Pharma
    [VIRTUAL] CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING C5 INHIBITORS (ePoster Area) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_3084;    
    Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening hematological disease associated with a significant burden of illness (BOI) due to complement-mediated hemolysis and a subsequent need for blood transfusions that often persists despite standard treatment with the C5 inhibitors eculizumab (ECU) or ravulizumab (RAV).  Findings from this BOI survey demonstrate that there is a significant unmet medical need among PNH patients, with a majority of PNH patients remaining anemic and reporting fatigue, and a notable number of PNH patients requiring blood transfusions, despite treatment with C5 inhibitors for at least 3 months.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Ultomiris IV (ravulizumab IV) / Alexion Pharma
    [VIRTUAL] CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING C5 INHIBITORS (ePoster Area) -  Feb 4, 2021 - Abstract #EBMT2021EBMT_3083;    
    Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening hematological disease associated with a significant burden of illness (BOI) due to complement-mediated hemolysis and a subsequent need for blood transfusions that often persists despite standard treatment with the C5 inhibitors eculizumab (ECU) or ravulizumab (RAV).  Findings from this BOI survey demonstrate that there is a significant unmet medical need among PNH patients, with a majority of PNH patients remaining anemic and reporting fatigue, and a notable number of PNH patients requiring blood transfusions, despite treatment with C5 inhibitors for at least 3 months.